Health Economics›Thyroid cancer›Advanced or metastatic disease

Advanced or metastatic disease

Thyroid cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Axitinib monotherapy Variant #01	—	R 21 402	28d	~9.2 mo	~20.9 mo	~2	~R 42 804 PFS proxy · indirect	4
Sorafenib monotherapy Variant #04	—	R 16 002	28d	~10.8 mo	—	~2	~R 32 005 PFS proxy · indirect	1
Doxorubicin monotherapy Variant #01	—	R 902	21d	~6.0 mo	~8.2 mo	~9	~R 8 114 PFS proxy · indirect	18
Selpercatinib monotherapy Variant #01 Partial	RET	—	28d	—	—	~2	—	1
Pralsetinib monotherapy Variant #01 Partial	RET	—	28d	—	—	~2	—	—

5 of 5 regimens shown